Abstract: The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel aza-bicycloalkane based cyclic peptides, acting as a targeting moiety towards integrin receptors.

Abstract: The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel aza-bicycloalkane based cyclic peptides, acting as a targeting moiety towards integrin receptors.

Abstract: The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel aza-bicycloalkane based cyclic peptides, acting as a targeting moiety towards integrin receptors.

Abstract: The present invention relates to compounds conformationally constrained mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.

Abstract: The present invention relates to compounds conformationally constrained mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.

Abstract: The present invention relates to novel hybrid cyclopeptide compounds embodying pyrrolidine- or piperidine-based amino acid substructures grafted onto a RGD (-Arg-Gly-Asp-) tripeptide sequence and acting as targeting ligands towards integrin receptors, intended, for example, for the treatment of altered angiogenic phenomena or for the preparation of therapeutically and/or diagnostically useful compounds; the invention also concerns a process for the synthesis of said cyclopeptides and biologically active derivatives thereof.

Abstract: The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel aza-bicycloalkane based cyclic peptides, acting as a targeting moiety towards integrin receptors.

Abstract: The invention relates to novel cyclic peptidomimetic compounds containing the sequence RGD for the preparation of appropriately functionalised antagonists of ?v?3 and ?v?5 integrins, and intended, for example, for the treatment of altered angiogenic phenomena or for the preparation of diagnostically useful compounds.

Abstract: The subject of the present invention are cyclic compounds, in particular having azabicycloalkane structures of the general formula (I) a process for their preparation, and their use as intermediates in the synthesis of biologically active peptidomimetic compounds containing the sequence RGD (Arg-Gly-Asp).

Abstract: Compounds of formula (I) where n is the number 0, 1 or 2, processes for the preparation together with methods for treating pathologies related to an altered &agr;v&bgr;3 integrin-mediated cell attachment, in particular where inhibition of angiogenesis is desired, for example in tumors, also associated with metastasis.

Abstract: The present invention discloses compounds of formula (I) wherein n is the number 0, 1 or 2. There are also disclosed processes for the preparation of the compounds, together with methods for treating pathologies related to an altered &agr;v&bgr;3 integrin-mediated cell attachment, in particular wherein the inhibition of angiogenesis is desired, for example in tumors, also associated with metastasis.

Abstract: The present invention discloses compounds of formula (I) 1

Abstract: The present invention discloses compounds of formula (I) wherein n is the number 0, 1 or 2. There are also disclosed processes for the preparation of said compounds, together with methods for treating pathologies related to an altered &agr;v&bgr;3 integrin-mediated cell attachment, in particular wherein the inhibition of angiogenesis is desired, for example in tumors, also associated with metastasis.

Abstract: The present invention discloses compounds of formula (I) 1

Abstract: Derivatives of bicyclic heterocycles comprising a pyrimidone ring fused to another 5, 6, or 7 membered nitrogen heterocycle which is C-substituted, through a methylene bridge, by a biphenyl group.

Abstract: Imidazole derivatives having A II antagonist activity, of Formula I, the processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof as therapeutic agents. The described compounds having A II antagonist activity can be used in various cardiovascular disorders.

Abstract: Compounds having a angiotensine II antagonistic activity ##STR1## Compounds of formula (I), wherein R, R.sub.1, R.sub.2, R.sub.3, X and Z groups have the meanings given in the specification and are endowed with AII antagonistic properties.

Abstract: Compounds of general formula (I) ##STR1## wherein E is O or S; R is C.sub.1 -C.sub.5 straight, branched or cyclic alkyl or C.sub.2 -C.sub.5 alkenyl; X can be H, F, Cl, Br, I, CF.sub.3 ; n is an integer 1 to 4; m is an integer 0 to 4; A and B are 5- or 6- membered aromatic carbocyclic rings optionally containing one or more heteroatoms selected from N, O, S and carrying the substituents R.sub.1, R.sub.2 and R.sub.3, respectively; R.sub.1 can be hydrogen, halogen, C.sub.1 -C.sub.4 alkoxycarbonyl, a sulfonic group or a tetrazole group of formula ##STR2## wherein R.sub.4 can be hydrogen or C.sub.1 -C.sub.5 alkyl; R.sub.2 can be hydrogen or a COOR.sub.4 group (wherein R.sub.4 is hydrogen or C.sub.1 -C.sub.5 alkyl), CN, SO.sub.3 H, PO.sub.3 H or a tetrazole group R.sub.3 ; can be a hydrogen or a moiety of formula (II)B'(R'.sub.2,R'.sub.3) (II)wherein: B.sup.1, R.sup.1.sub.2 have the same meanings reported above for B and R.sub.2, R'.sub.3 is H; with the proviso that when A is phenyl, R.sub.

Abstract: Pharmaceutical compositions for the treatment of peripheral neuropathies of dysmetabolic or toxic origin and of cerebropathies of organic and functional origin, containing as the active ingredient L-.alpha.-glycerophosphoryl-D-myo-inosital, as such or as the alkali or alkali-earth metal salt thereof.

Abstract: Pharmaceutical compositions for enhancing the process of learning and memory are disclosed, that contain as active principle a 3-amino-.epsilon.-caprolactam of formula (1) ##STR1## Wherein R is selected from the group consisting of hydrogen, formyl and acetyl.Orally or parenterally administrable pharmaceutical compositions in unit dosage form comprise from about 100 to about 500 mg of a compound of formula (1).